Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.73 |
| ▸ | CLK2 | P49760 | 3/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.73 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.73 |
| ▸ | GSK3B | P49841 | 2/20 | 0.73 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.73 |
| ▸ | CLK1 | P49759 | 2/20 | 0.73 |
| ▸ | CLK3 | P49761 | 1/20 | 0.73 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.73 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.73 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.71 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2455100 | 0.85 | GSK3B (1.00) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL27839423 | 0.83 | FGFR1 (0.71) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL14663812 | 0.83 | FGFR1 (1.00) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL27976107 | 0.83 | CLK1 (0.74) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL13115655 | 0.83 | FGFR1 (0.71) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL16935421 | 0.82 | FGFR1 (1.00) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL8266373 | 0.82 | FGFR1 (0.70) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL8264120 | 0.82 | FGFR1 (0.70) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL11295 | 0.79 | FGFR1 (0.65) | FGFR1DYRK1ACLK2CLK4DYRK3 | |
| SCHEMBL28104327 | 0.79 | FGFR1 (0.65) | FGFR1DYRK1ACLK2CLK4DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-3592742-B1 | JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-103717599-B | Indazole | PFIZER LTD. (GB) | 2015-11-25 | — | — | CN | disclosed |
| EP-2736907-B1 | INDAZOLES | PFIZER LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| CN-102939283-B | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-06-03 | — | — | CN | disclosed |
| US-8895544-B2 | Indazoles | PFIZER LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| CN-103717599-A | Indazoles | PFIZER | 2014-04-09 | — | — | CN | disclosed |
| US-20140024634-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| US-8575336-B2 | Indazoles | PFIZER LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| CN-102939283-A | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV | 2013-02-20 | — | — | CN | disclosed |
| US-20130029968-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20110237633-A1 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029968-A1 | INDAZOLES | CYP11B2, CYP11B1, IL33 | FGFR1 2302/4885DYRK1A 3287/4885CLK2 1919/4885 |
| US-20110237633-A1 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | HGF, HDGF, MET | FGFR1 11/4885DYRK1A 4134/4885CLK2 3759/4885 |
| US-20140024634-A1 | INDAZOLES | JAK1, JAK3, JAK2 | FGFR1 699/4885DYRK1A 854/4885CLK2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.